The present invention provides a transdermal patch comprising an adhesive layer on a backing, wherein the adhesive layer comprises a drug, DMSO, and an adhesive base, and the adhesive base comprises a styrene-based thermoplastic elastomer having a triblock content of 35% to 65%.

Provided herein is a water- and sweat-resistant transdermal drug delivery system for application to the skin of a mammal that comprises a patch having a diameter between 1 and 8 cm in length and a surface area between 4 and 8 cm.sup.2. Also provided are methods of producing the transdermal drug delivery system and methods of treatment comprising the use of the transdermal drug delivery system.

The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer.

The present invention relates to transdermal therapeutic systems for the transdermal administration of rotigotine containing a therapeutically effective amount of rotigotine base in a self-adhesive layer structure that includes a backing layer and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase formed from a polymer or a polymer mixture along with an inner phase that includes rotigotine base and a polymer mixture including polyvinylpyrrolidone having a K-Value of at least 80 and at least one further hydrophilic polymer selected from the polymer groups: copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The inner phase forms dispersed deposits in the outer phase. The inventive transdermal therapeutic systems optionally include a skin contact layer.

Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

The present invention relates to composition of polyherbal transdermal patch comprising combination of natural herbal extracts as active ingredients and pharmaceutically acceptable excipients. The present invention relates to composition of polyherbal transdermal patch comprising combination of natural herbal extracts includes boswellia extract, evening primrose oil, blackcurrant seed oil, Ginger, Licorice, Cats claw and Devil's claw and other pharmaceutically acceptable excipients. The present invention also relates to composition of polyherbal transdermal patch comprising boswellia extract, evening primrose oil, blackcurrant seed oil, Ginger, Licorice, Cats claw and Devil's claw as natural herbal ingredients and pharmaceutically acceptable excipients for the treatment/management of pain. The present invention also relates to an efficient process for the preparation of polyherbal transdermal patch by using hot-melt coating technique (HMC), comprising the steps of melting, mixing, coating, laminating, cutting, pouching and labelling.

A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

The present invention provides a rotigotine stabilization method for stabilizing rotigotine and/or a pharmaceutically acceptable salt thereof in a rotigotine-containing patch comprising a backing layer and an adhesive agent layer, the adhesive agent layer containing the rotigotine and/or the pharmaceutically acceptable salt thereof and a styrene-based thermoplastic elastomer, the method comprising further incorporating cross-linked polyvinylpyrrolidone in the adhesive agent layer in a content of 3 to 25% by mass in the adhesive agent layer.

A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible.

The present invention relates to a donepezil eutectic mixture and a use thereof. A eutectic mixture of the present invention allows increased solubility and skin permeability of donepezil, and a pharmaceutical composition including the same does not generate donepezil crystals and maintains amorphous form even when stored under various conditions, thereby being applicable to various formulations while also having excellent stability and efficacy.